C&EN White Paper
Addressing challenges across the virus like particle manufacturing workflow
Brought to you by Thermo Fisher Scientific

Virus like particles are a powerful platform to generate highly immunogenic vaccines, particularly for viruses that are mutating frequently. These particles are made from viral proteins that self-assemble into a structure resembling a virus’s outer shell. Vaccines based on virus like particles for hepatitis B and human papillomavirus are available commercially.

An integrated system of tools for protein expression, purification, and quality control testing can help support efficient and cost-effective virus like particle production on a commercial scale.

Key Objectives:
  • Baculovirus-based protein expression systems offer a flexible platform for generating virus-like particles
  • Affinity-based capture techniques can speed purification and polishing steps
  • Quantitative detection of nucleic acids can be used for biotherapeutic quality control testing

Brought to you by:
Thermo Fisher Scientific
Please complete the form to download the white paper.

*I can withdraw my consent and unsubscribe at any time by e-mailing reply@thermofisher.com . By submitting my data, I give consent to the collection, processing and use of my personal data in accordance with the Thermo Fisher Scientific Privacy Policy .
*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) and its sponsor via email. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy .

Copyright © 2024 American Chemical Society | 1155 Sixteenth Street NW | Washington, DC 20036 | View our Privacy Policy